Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis

The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%–20% of high- and very-high-risk patients do not reach their LDL-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogula, Sylwester, Błażejowska, Ewelina, Gąsecka, Aleksandra, Szarpak, Łukasz, Jaguszewski, Milosz J., Mazurek, Tomasz, Filipiak, Krzysztof J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199585/
https://www.ncbi.nlm.nih.gov/pubmed/34199468
http://dx.doi.org/10.3390/jcm10112467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199585/
https://www.ncbi.nlm.nih.gov/pubmed/34199468
http://dx.doi.org/10.3390/jcm10112467

Ejemplares similares